Sculpta builds Protein Sculpting™ therapeutics that modify the structure and function of disease‑causing proteins to treat neurodegeneration and brain aging. Their platform leverages the most comprehensive single‑cell data across the human brain and body to identify and engineer targets, aiming to reverse up to 90% of age‑related brain disorders. By integrating computational biology, machine learning, and large‑scale data pipelines, Sculpta accelerates discovery of novel neurotherapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative and age‑related brain disorders affect a growing portion of the population, yet existing therapeutics often target downstream symptoms rather than the underlying disease‑causing proteins, limiting efficacy and the ability to halt disease progression.
Solution
Sculpta’s Protein Sculpting™ platform modifies the structure and function of disease‑causing proteins to treat neurodegeneration and brain aging. The platform leverages the most comprehensive single‑cell RNA and splicing atlas of the human brain and body to identify isoform‑specific targets with high precision. Computational biology, machine‑learning models, and nucleic‑acid engineering are integrated to design molecules that can reshape protein activity. By targeting the root molecular mechanisms, the approach aims to reverse a large proportion of age‑linked neurological conditions and accelerate preclinical development of neurotherapeutics.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for neurodegenerative and age‑related brain diseases, as well as academic research groups focused on protein‑targeted therapeutics.
Features
- Proprietary Human Splicing Atlas providing single‑cell resolution of RNA isoform expression across tissues
- Machine‑learning‑driven target discovery pipeline that prioritizes disease‑relevant protein isoforms
- Nucleic‑acid engineering tools for designing molecules that remodel protein structure and function
- Integrated computational biology workflows that streamline target validation and lead optimization
- Platform capability to address up to 90% of age‑related brain disorders through protein‑level intervention